Targeting a specific protein to improve treatment for prostate cancer
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy
This study is looking at how a specific protein might help us find better treatments for men with castration-resistant prostate cancer, which is a tough type of cancer that doesn't respond to usual therapies, and it aims to discover new ways to slow down tumor growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10877840 on NIH RePORTER |
What this research studies
This research focuses on enhancing treatment options for patients with castration-resistant prostate cancer (CRPC), a severe form of prostate cancer that does not respond to standard therapies. The study aims to investigate the role of a protein called Polo-like kinase 1 (Plk1) in regulating cellular responses to stress and its impact on tumor growth. By exploring the Plk1/p62/Nrf2 signaling pathway, researchers hope to identify new therapeutic strategies that could improve patient outcomes. The approach includes laboratory experiments and mouse models to test the effectiveness of inhibiting this pathway in cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have limited treatment options.
Not a fit: Patients with early-stage prostate cancer or those who do not have castration-resistant prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with advanced prostate cancer, potentially extending survival and improving quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Li, Zhiguo — University of Kentucky
- Study coordinator: Li, Zhiguo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.